Based on our preclinical evidence, we posit that clinical trials are required to evaluate the efficacy of AZD9291 treatment in EGFR-mutant lung cancer patients with CNS metastasis including LMC with or without resistance to other EGFR-TKIs. The gene discussed is EGFR; the disease is lung cancer.